Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme
Class IITerminatedD-1087-2023

Drug recall · August 30, 2023

Rufinamide Tablets recall

Why: cGMP deviations: Batch was released prior to approval.

Class II: could cause temporary or reversible health problems; serious harm is remote.

The recall

Product

Rufinamide Tablets, USP 200 mg, packaged in 120-count bottle, Rx only, Distributed by: Aurobindo Pharma USA, Inc., 279 Princeton-Hightstown Road, East Windsor, NJ 08520, Made in India, NDC 59651-616-08

Lots / codes

Lot #: RB2023001A, Exp 02/2025

Quantity
48 bottles
Company
Aurobindo Pharma USA Inc., East Windsor, NJ
Distribution
USA nationwide
Initiated
July 21, 2023 · Voluntary: Firm initiated
Classified
August 18, 2023
Reported
August 30, 2023
Ended
February 26, 2024
How notified
Letter

The drug: prices, other makers, shortages

If you have this product

  1. Check the lot number on your package against the lots above. Only those lots are recalled.
  2. Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
  3. Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
  4. Return or dispose of recalled product as the company or your pharmacy advises.

Recalled with it (same recall event)

Questions about this recall

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Watch Rufinamide

One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.